Paclitaxel-MVCP | MC-Val-Cit-PAB-Paclitaxel | Paclitaxel conjugate

MedKoo Cat#: 620102 | Name: Paclitaxel-MVCP

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Paclitaxel-MVCP, also known as MC-Val-Cit-PAB-Paclitaxel, is a paclitaxel derivative with a MC-Val-Cit-PAB linker. Mc-Val-Cit-PAB is a cathepsin cleavable ADC peptide linker. Paclitaxel-MVCP can be used to conjugate with other molecules such as peptides, proteins, antibodies or enzymes, or polymers. Paclitaxel-MVCP is a useful agent to make Paclitaxel-conjugate for drug delivery, nanodrug research.

Chemical Structure

Paclitaxel-MVCP

CAS#Paclitaxel-MVCP

Theoretical Analysis

MedKoo Cat#: 620102

Name: Paclitaxel-MVCP

CAS#: Paclitaxel-MVCP

Chemical Formula: C76H89N7O22

Exact Mass: 1451.6061

Molecular Weight: 1452.58

Elemental Analysis: C, 62.84; H, 6.18; N, 6.75; O, 24.23

Price and Availability

Size	Price	Availability
1mg	USD 150.00	Ready to ship
2mg	USD 250.00	Ready to ship
5mg	USD 550.00	Ready to ship
10mg	USD 950.00	Ready to ship
25mg	USD 2,050.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

186040-50-6 (ceribate) 33069-62-4 (free base) 263351-82-2 (Poliglumex) Paclitaxel-SMCC 117527-50-1 (Paclitaxel-Succinic acid) Paclitaxel-MVCP

Synonym

Paclitaxel-MVCP; MC-Val-Cit-PAB-Paclitaxel, Paclitaxel conjugate.

IUPAC/Chemical Name

(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-((((4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl)oxy)carbonyl)oxy)-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate

InChi Key

WKCOFIXYDRGLSO-WMBYQXBNSA-N

InChi Code

InChI=1S/C76H89N7O22/c1-42(2)59(81-55(87)29-19-12-20-37-83-56(88)34-35-57(83)89)68(93)80-51(28-21-36-78-71(77)96)67(92)79-50-32-30-46(31-33-50)40-99-72(97)103-62(60(47-22-13-9-14-23-47)82-66(91)48-24-15-10-16-25-48)70(95)102-52-39-76(98)65(104-69(94)49-26-17-11-18-27-49)63-74(8,53(86)38-54-75(63,41-100-54)105-45(5)85)64(90)61(101-44(4)84)58(43(52)3)73(76,6)7/h9-11,13-18,22-27,30-35,42,51-54,59-63,65,86,98H,12,19-21,28-29,36-41H2,1-8H3,(H,79,92)(H,80,93)(H,81,87)(H,82,91)(H3,77,78,96)/t51-,52-,53-,54+,59-,60-,61+,62+,63-,65-,74+,75-,76+/m0/s1

SMILES Code

O=C(C1=CC=CC=C1)O[C@H]([C@@]2(C[C@@H](C(C)=C([C@H]3OC(C)=O)C2(C)C)OC([C@H](OC(OCC(C=C4)=CC=C4NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN5C(C=CC5=O)=O)=O)=O)=O)=O)[C@H](C6=CC=CC=C6)NC(C7=CC=CC=C7)=O)=O)O)[C@]8([H])[C@@]9(CO[C@@]9(C[C@@H]([C@@](C3=O)8C)O)[H])OC(C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Please also see similar products: #610235: MC-Val-Cit-PAB (ADC peptide linker) #610234: MC-Val-Cit-PAB-PNP (ADC peptide linker)

Certificate of Analysis

View CoA: current batch, Lot#YXM71016

QC Data

View QC data: current batch, Lot#YXM71016

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,452.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Yan Q, Yang Y, Chen W, Hu J, Yang D. Construction of polymer-paclitaxel conjugate linked via a disulfide bond. Mater Sci Eng C Mater Biol Appl. 2016 Jan 1;58:580-5. doi: 10.1016/j.msec.2015.09.025. Epub 2015 Sep 10. PubMed PMID: 26478347. 2: Yin S, Huai J, Chen X, Yang Y, Zhang X, Gan Y, Wang G, Gu X, Li J. Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid. Acta Biomater. 2015 Oct 15;26:274-85. doi: 10.1016/j.actbio.2015.08.029. Epub 2015 Aug 20. PubMed PMID: 26300335. 3: He X, Lin M, Lu T, Qu Z, Xu F. Molecular analysis of interactions between a PAMAM dendrimer-paclitaxel conjugate and a biomembrane. Phys Chem Chem Phys. 2015 Nov 28;17(44):29507-17. doi: 10.1039/c5cp02242h. Epub 2015 Aug 10. PubMed PMID: 26256278. 4: Wu D, Zheng Y, Hu X, Fan Z, Jing X. Anti-tumor activity of folate targeted biodegradable polymer-paclitaxel conjugate micelles on EMT-6 breast cancer model. Mater Sci Eng C Mater Biol Appl. 2015 Aug;53:68-75. doi: 10.1016/j.msec.2015.04.012. Epub 2015 Apr 14. PubMed PMID: 26042692. 5: Du AW, Lu H, Stenzel MH. Core-Cross-Linking Accelerates Antitumor Activities of Paclitaxel-Conjugate Micelles to Prostate Multicellular Tumor Spheroids: A Comparison of 2D and 3D Models. Biomacromolecules. 2015 May 11;16(5):1470-9. doi: 10.1021/acs.biomac.5b00282. Epub 2015 Apr 17. PubMed PMID: 25857405. 6: Ma P, Zhang X, Ni L, Li J, Zhang F, Wang Z, Lian S, Sun K. Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumab. Int J Nanomedicine. 2015 Mar 18;10:2173-90. doi: 10.2147/IJN.S77152. eCollection 2015. PubMed PMID: 25834432; PubMed Central PMCID: PMC4370923. 7: Peng L, Schorzman AN, Ma P, Madden AJ, Zamboni WC, Benhabbour SR, Mumper RJ. 2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model. Int J Nanomedicine. 2014 Jul 30;9:3601-10. doi: 10.2147/IJN.S66040. eCollection 2014. PubMed PMID: 25114529; PubMed Central PMCID: PMC4124067. 8: Oyama T, Takeuchi H, Matsuda S, Ozawa S, Kitajima M, Kitagawa Y. Translymphatic chemotherapy targeting sentinel lymph nodes using a novel phospholipid polymer-Paclitaxel conjugate. Anticancer Res. 2014 Apr;34(4):1751-7. PubMed PMID: 24692706. 9: Caron J, Maksimenko A, Wack S, Lepeltier E, Bourgaux C, Morvan E, Leblanc K, Couvreur P, Desmaële D. Improving the antitumor activity of squalenoyl-paclitaxel conjugate nanoassemblies by manipulating the linker between paclitaxel and squalene. Adv Healthc Mater. 2013 Jan;2(1):172-85. doi: 10.1002/adhm.201200099. Epub 2012 Dec 4. PubMed PMID: 23213041. 10: Ma P, Rahima Benhabbour S, Feng L, Mumper RJ. 2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer. Cancer Lett. 2013 Jul 1;334(2):253-62. doi: 10.1016/j.canlet.2012.08.009. Epub 2012 Aug 16. PubMed PMID: 22902506; PubMed Central PMCID: PMC3522796. 11: Liang L, Lin SW, Dai W, Lu JK, Yang TY, Xiang Y, Zhang Y, Li RT, Zhang Q. Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity. J Control Release. 2012 Jun 28;160(3):618-29. doi: 10.1016/j.jconrel.2012.02.020. Epub 2012 Mar 3. PubMed PMID: 22410114. 12: Wang Z, Hu X, Yue J, Jing X. Experimental study on biodegradable polymer-paclitaxel conjugate micelles for chemotherapy of C6 glioma. J Control Release. 2011 Nov 30;152 Suppl 1:e41-2. doi: 10.1016/j.jconrel.2011.08.110. PubMed PMID: 22195914. 13: Yang D, Van S, Liu J, Wang J, Jiang X, Wang Y, Yu L. Physicochemical properties and biocompatibility of a polymer-paclitaxel conjugate for cancer treatment. Int J Nanomedicine. 2011;6:2557-66. doi: 10.2147/IJN.S25044. Epub 2011 Oct 21. PubMed PMID: 22072890; PubMed Central PMCID: PMC3205149. 14: Galer CE, Sano D, Ghosh SC, Hah JH, Auzenne E, Hamir AN, Myers JN, Klostergaard J. Hyaluronic acid-paclitaxel conjugate inhibits growth of human squamous cell carcinomas of the head and neck via a hyaluronic acid-mediated mechanism. Oral Oncol. 2011 Nov;47(11):1039-47. doi: 10.1016/j.oraloncology.2011.07.029. Epub 2011 Sep 7. PubMed PMID: 21903450. 15: Li S, Gray BP, McGuire MJ, Brown KC. Synthesis and biological evaluation of a peptide-paclitaxel conjugate which targets the integrin αvβ₆. Bioorg Med Chem. 2011 Sep 15;19(18):5480-9. doi: 10.1016/j.bmc.2011.07.046. Epub 2011 Aug 4. PubMed PMID: 21868241; PubMed Central PMCID: PMC3195361. 16: Wan Y, Zheng Y, Song X, Hu X, Liu S, Tong T, Jing X. Anti-tumor activity of biodegradable polymer-paclitaxel conjugate micelles on Lewis lung cancer mice models. J Biomater Sci Polym Ed. 2011;22(9):1131-46. doi: 10.1163/092050610X500570. PubMed PMID: 20594407. 17: Zhang SQ, Song YN, He XH, Zhong BH, Zhang ZQ. Liquid chromatography-tandem mass spectrometry for the determination of paclitaxel in rat plasma after intravenous administration of poly(L-glutamic acid)-alanine-paclitaxel conjugate. J Pharm Biomed Anal. 2010 Apr 6;51(5):1169-74. doi: 10.1016/j.jpba.2009.11.030. Epub 2009 Dec 4. PubMed PMID: 20036092. 18: Chun C, Lee SM, Kim SY, Yang HK, Song SC. Thermosensitive poly(organophosphazene)-paclitaxel conjugate gels for antitumor applications. Biomaterials. 2009 Apr;30(12):2349-60. doi: 10.1016/j.biomaterials.2008.12.083. PubMed PMID: 19178941. 19: Ryppa C, Mann-Steinberg H, Biniossek ML, Satchi-Fainaro R, Kratz F. In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3. Int J Pharm. 2009 Feb 23;368(1-2):89-97. doi: 10.1016/j.ijpharm.2008.09.055. Epub 2008 Oct 17. PubMed PMID: 18992308. 20: Lee H, Lee K, Park TG. Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity. Bioconjug Chem. 2008 Jun;19(6):1319-25. doi: 10.1021/bc8000485. Epub 2008 May 16. PubMed PMID: 18481885.